Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Mar 16, 2017 (10 years ago)

Fluphenazine Decanoate Injection

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Subpotent Drug

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Fluphenazine Decanoate Injection, USP; 25 mg/mL, 5mL vials, Rx only, APP Pharmaceuticals, LLC Schaumburg, IL 60173, NDC 63323-0272-05

Affected NDC 63323-0272-05

Compare with the code on your package — it is the most precise check available.

Drug: Fluphenazine

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Fluphenazine Decanoate
NDC 63323-0272
25 mg/mL Injection, Solution
Intramuscular|subcutaneous
Fresenius Kabi USA, LLC Rx
Recalling firm
Fresenius Kabi USA, LLC
NDC code
63323-0272-05
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0647-2017 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Fluphenazine recalls

See all
Class III · Low risk

Fluphenazine Hydrochloride Tablets

Failed impurities/degradation specifications: (OOS) for Organic Impurities by HPLC (Impurity-A) during testing at the 18 months long term stability. Result: 1.1 percent. Spec: 1.0 percent.

Ongoing Impurity / degradation Ajanta Pharma USA Inc NDC 27241-255-01 D-0836-2026

Other recalls by Fresenius Kabi USA, LLC

All 2017 recalls
Class I · High risk

Tyenne (tocilizumab-aazg)

Presence of particulate matter:An internal investigation at the firm found the product to contain glass particles.

Ongoing Particulate / foreign matter Fresenius Kabi USA, LLC NDC 65219-594-20 D-0827-2026
Class I · High risk

Morphine Sulfate Injection

Labeling: Label Mixup: MicroVault labeled as Morphine 2 mg/1 mL, contains a Prefilled Syringe of Dilaudid 0.5 mg/0.5 mL.

Ongoing Labeling / mix-up Fresenius Kabi USA, LLC D-0788-2026